Quince Therapeutics, Inc.QNCXNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank71
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Percentile
P71
Within normal range
vs 2Y Ago
-5.6x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
2024-2.49-107.4%
2023-1.20-368.4%
20220.45+113.1%
2021-3.41+64.0%
2020-9.47+63.7%
2019-26.10+54.0%
2018-56.67+17.4%
2017-68.63-